A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab

BACKGROUND: The combination of the immune checkpoint inhibitors (ICIs) ipilimumab and nivolumab is a mainstay of treatment for selected patients with metastatic melanoma. This combination also results in more frequent immune-related adverse events (irAEs) than either ICI alone. These irAEs can be se...

Descripción completa

Detalles Bibliográficos
Autores principales: Olson, Daniel J, Rajagopal, Padma, Tjota, Melissa Y, Venkataraman, Girish, Luke, Jason J, Gajewski, Thomas F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069276/
https://www.ncbi.nlm.nih.gov/pubmed/32169870
http://dx.doi.org/10.1136/jitc-2019-000380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069276/
https://www.ncbi.nlm.nih.gov/pubmed/32169870
http://dx.doi.org/10.1136/jitc-2019-000380

Ejemplares similares